California 2023-2024 Regular Session

California Assembly Bill AR58 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	CALIFORNIA LEGISLATURE 20232024 REGULAR SESSION House Resolution No. 58Introduced by Assembly Member JacksonSeptember 06, 2023 Relative to access to care.LEGISLATIVE COUNSEL'S DIGESTHR 58, as introduced, Jackson. Digest KeyBill TextWHEREAS, Reliable and safe access to medical care includes reliable access to psychiatric medications; andWHEREAS, Efforts to reduce mental health stigma, increase mental health awareness, and improve recognition of attention deficit hyperactivity disorder (ADHD) by healthcare providers, parents, and teachers, along with changes in ADHD diagnostic criteria, have led to an increase in ADHD diagnoses and increased demand for stimulants over the past few decades; and WHEREAS, The increased recognition and need for treatment of ADHD has led to a recent shortage of ADHD medications in the United States that represents an urgent mental health crisis with potential for irreparable harm to patients; and WHEREAS, The irreparable harm from a lack of access to ADHD medications accrues to: (1) children who regress behaviorally and academically; (2) adults who have been successfully treated with ADHD medications for years but are now unable to perform in their jobs and function in other areas of life; and (3) communities that are experiencing increasing illicit substance distribution, car accidents, and prevalence of depression, anxiety, and other comorbidities of untreated ADHD; andWHEREAS, The power of the federal Drug Enforcement Agency (DEA) to limit the supply of ADHD medications should be exercised in a way that responds to shortages in medically necessary medications in a coordinated manner to ensure access by patients that require those medications to treat disabling ADHD; andWHEREAS, The DEA has thus far declined to increase the quotas that it has imposed to limit access by pharmaceutical manufacturers to the materials necessary to produce ADHD medications, despite calls from those manufacturers to increase the quotas to meet current demand; and WHEREAS, The DEA has presented no justification for maintaining the quotas beyond its unsubstantiated claims that the manufacturers already have enough materials to produce ADHD medications; andWHEREAS, There is ongoing damage to the health of Californians with ADHD imposed by the current critical shortage of medication to treat this condition; andWHEREAS, There is a necessity of requesting federal action to remove any unjustified barriers to increase the supply of medications that are created by DEA quotas that limit the availability of ingredients essential to produce these medications by legitimate manufacturers; now, therefore, be itResolved by the Assembly of the State of California, That the Assembly urges the California Health and Human Services Agency (CHHS) to act to: (1) hold pharmaceutical companies, distributors, and pharmacies accountable for taking actions to ameliorate the current ADHD medication shortage and develop initiatives for the prevention and management of further shortages of ADHD medications and (2) urgently meet with United States Department of Health and Human Services, and the federal Drug Enforcement Agency regarding modification of any insufficiently justified quotas on the supply of ingredients to manufacturers of critical ADHD medications; and be it furtherResolved, That The Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
2	2
3	3	CALIFORNIA LEGISLATURE 20232024 REGULAR SESSION House Resolution No. 58Introduced by Assembly Member JacksonSeptember 06, 2023 Relative to access to care.LEGISLATIVE COUNSEL'S DIGESTHR 58, as introduced, Jackson. Digest Key
4	4
5	5
6	6
7	7
8	8
9	9	CALIFORNIA LEGISLATURE 20232024 REGULAR SESSION
10	10
11	11	House Resolution
12	12
13	13	No. 58
14	14
15	15	Introduced by Assembly Member JacksonSeptember 06, 2023
16	16
17	17	Introduced by Assembly Member Jackson
18	18	September 06, 2023
19	19
20	20	Relative to access to care.
21	21
22	22	LEGISLATIVE COUNSEL'S DIGEST
23	23
24	24	## LEGISLATIVE COUNSEL'S DIGEST
25	25
26	26	HR 58, as introduced, Jackson.
27	27
28	28
29	29
30	30	## Digest Key
31	31
32	32	## Bill Text
33	33
34	34	WHEREAS, Reliable and safe access to medical care includes reliable access to psychiatric medications; and
35	35
36	36	WHEREAS, Efforts to reduce mental health stigma, increase mental health awareness, and improve recognition of attention deficit hyperactivity disorder (ADHD) by healthcare providers, parents, and teachers, along with changes in ADHD diagnostic criteria, have led to an increase in ADHD diagnoses and increased demand for stimulants over the past few decades; and
37	37
38	38	WHEREAS, The increased recognition and need for treatment of ADHD has led to a recent shortage of ADHD medications in the United States that represents an urgent mental health crisis with potential for irreparable harm to patients; and
39	39
40	40	WHEREAS, The irreparable harm from a lack of access to ADHD medications accrues to: (1) children who regress behaviorally and academically; (2) adults who have been successfully treated with ADHD medications for years but are now unable to perform in their jobs and function in other areas of life; and (3) communities that are experiencing increasing illicit substance distribution, car accidents, and prevalence of depression, anxiety, and other comorbidities of untreated ADHD; and
41	41
42	42	WHEREAS, The power of the federal Drug Enforcement Agency (DEA) to limit the supply of ADHD medications should be exercised in a way that responds to shortages in medically necessary medications in a coordinated manner to ensure access by patients that require those medications to treat disabling ADHD; and
43	43
44	44	WHEREAS, The DEA has thus far declined to increase the quotas that it has imposed to limit access by pharmaceutical manufacturers to the materials necessary to produce ADHD medications, despite calls from those manufacturers to increase the quotas to meet current demand; and
45	45
46	46	WHEREAS, The DEA has presented no justification for maintaining the quotas beyond its unsubstantiated claims that the manufacturers already have enough materials to produce ADHD medications; and
47	47
48	48	WHEREAS, There is ongoing damage to the health of Californians with ADHD imposed by the current critical shortage of medication to treat this condition; and
49	49
50	50	WHEREAS, There is a necessity of requesting federal action to remove any unjustified barriers to increase the supply of medications that are created by DEA quotas that limit the availability of ingredients essential to produce these medications by legitimate manufacturers; now, therefore, be it
51	51
52	52	Resolved by the Assembly of the State of California, That the Assembly urges the California Health and Human Services Agency (CHHS) to act to: (1) hold pharmaceutical companies, distributors, and pharmacies accountable for taking actions to ameliorate the current ADHD medication shortage and develop initiatives for the prevention and management of further shortages of ADHD medications and (2) urgently meet with United States Department of Health and Human Services, and the federal Drug Enforcement Agency regarding modification of any insufficiently justified quotas on the supply of ingredients to manufacturers of critical ADHD medications; and be it further
53	53
54	54	Resolved, That The Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.